Qifang Jin

Dr. Qifang Jin


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 July 2018 in Experimental and Therapeutic Medicine
Verified
Journal Article
Open access
PDF file
QJQifang Jin
Qifang Jin
WHWenfeng He
Wenfeng He
LCLeifeng Chen
Leifeng Chen
YYYang Yang
Yang Yang
KSKe Shi
Ke Shi
ZYZhipeng You
Zhipeng You
Retinoblastoma is the most frequent intraocular malignant tumor type to occur in childhood. MicroRNA (miR)‑101‑3p has been reported to function as a tumor suppressor in various types of cancer. However, the biological function and underlying mechanisms of miR‑101‑3p in retinoblastoma are largely unknown. In the present study, it was identified that miR‑101‑3p was downregulated in retinoblastoma. MTT and flow cytometry assays demonstrated that ectopic overexpression of miR‑101‑3p significantly inhibited cell viability and cell cycle progression in WERI‑Rb‑1 and Y79 cells. In vivo mouse experiments further confirmed the anti‑proliferative role of miR‑101‑3p in retinoblastoma. Additionally, predictions with TargetScan software indicated that the 3'‑untranslated regions of enhancer of zeste homolog 2 (EZH2) and histone deacetylase (HDAC9) mRNAs are targeted by miR‑101‑3p. Accordingly, a dual luciferase reporter gene assay demonstrated that miR‑101‑3p directly targeted EZH2 and HDAC9 to suppress the proliferation of retinoblastoma cells. Meanwhile, the restoration of EZH2 or HDAC9 expression countered the anti‑proliferative effect of miR‑101‑3p on WERI‑Rb‑1 and Y79 cells. Collectively, these data highlight the role of miR‑101‑3p in the tumorigenesis of retinoblastoma, and indicate its suitability as a novel therapeutic target.

3 March 2026 in Nanomedicine: Nanotechnology, Biology and Medicine
Verified
Journal Article
Closed access
QWQian Wang
Qian Wang
YLYanxia Li
Yanxia Li
WWWeiqi Wu
Weiqi Wu
SQShiqi Qin
Shiqi Qin
ZXZhiqi Xiong
Zhiqi Xiong
YXYu Xiong
Yu Xiong